| Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin DS Wang, JW Jonker, Y Kato, H Kusuhara, AH Schinkel, Y Sugiyama Journal of Pharmacology and Experimental Therapeutics 302 (2), 510-515, 2002 | 570 | 2002 |
| Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system N Nishiyama, Y Kato, Y Sugiyama, K Kataoka Pharmaceutical research 18, 1035-1041, 2001 | 255 | 2001 |
| Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin DS Wang, H Kusuhara, Y Kato, JW Jonker, AH Schinkel, Y Sugiyama Molecular pharmacology 63 (4), 844-848, 2003 | 245 | 2003 |
| Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats M Masuda, Y I'izuka, M Yamazaki, R Nishigaki, Y Kato, K Ni'inuma, ... Cancer Research 57 (16), 3506-3510, 1997 | 227 | 1997 |
| Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1 Y Kato, Y Kubo, D Iwata, S Kato, T Sudo, T Sugiura, T Kagaya, ... Pharmaceutical research 27, 832-840, 2010 | 215 | 2010 |
| Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats XY Chu, Y Kato, K Niinuma, KI Sudo, H Hakusui, Y Sugiyama Journal of Pharmacology and Experimental Therapeutics 281 (1), 304-314, 1997 | 204 | 1997 |
| Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of … Y Gotoh, H Suzuki, S Kinoshita, T Hirohashi, Y Kato, Y Sugiyama Journal of Pharmacology and Experimental Therapeutics 292 (1), 433-439, 2000 | 193 | 2000 |
| Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells Y Sai, Y Kaneko, S Ito, K Mitsuoka, Y Kato, I Tamai, P Artursson, A Tsuji Drug metabolism and disposition 34 (8), 1423-1431, 2006 | 189 | 2006 |
| Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes H Matsuo, K Yamamoto, H Nakaoka, A Nakayama, M Sakiyama, T Chiba, ... Annals of the rheumatic diseases 75 (4), 652-659, 2016 | 180 | 2016 |
| Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats XY Chu, Y Kato, Y Sugiyama Cancer Research 57 (10), 1934-1938, 1997 | 173 | 1997 |
| Importance of the liver in plasma clearance of hepatocyte growth factors in rats KX Liu, Y Kato, M Narukawa, DC Kim, M Hanano, O Higuchi, T Nakamura, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 263 (5 …, 1992 | 146 | 1992 |
| Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific … Y Sugiyama, Y Kato, X Chu Cancer chemotherapy and pharmacology 42, S44-S49, 1998 | 142 | 1998 |
| Function of uptake transporters for taurocholate and estradiol 17β-d-glucuronide in cryopreserved human hepatocytes Y Shitara, AP Li, Y Kato, C Lu, K Ito, T Itoh, Y Sugiyama Drug metabolism and pharmacokinetics 18 (1), 33-41, 2003 | 139 | 2003 |
| Comparative inhibitory effects of different compounds on rat Oatp1 (Slc21a1)-and Oatp2 (Slc21a5)-mediated transport Y Shitara, D Sugiyama, H Kusuhara, Y Kato, T Abe, PJ Meier, T Itoh, ... Pharmaceutical research 19, 147-153, 2002 | 135 | 2002 |
| The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites M Horikawa, Y Kato, CA Tyson, Y Sugiyama Drug metabolism and pharmacokinetics 17 (1), 23-33, 2002 | 129 | 2002 |
| Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters XY Chu, Y Kato, K Ueda, H Suzuki, K Niinuma, CA Tyson, V Weizer, ... Cancer research 58 (22), 5137-5143, 1998 | 118 | 1998 |
| Active efflux of CPT-11 and its metabolites in human KB-derived cell lines XY Chu, H Suzuki, K Ueda, Y Kato, SI Akiyama, Y Sugiyama Journal of Pharmacology and Experimental Therapeutics 288 (2), 735-741, 1999 | 116 | 1999 |
| A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU Y Tsukamoto, Y Kato, M Ura, I Horii, H Ishitsuka, H Kusuhara, Y Sugiyama Pharmaceutical research 18, 1190-1202, 2001 | 107 | 2001 |
| Displays of paternal mouse pup retrieval following communicative interaction with maternal mates HX Liu, O Lopatina, C Higashida, H Fujimoto, S Akther, A Inzhutova, ... Nature communications 4 (1), 1346, 2013 | 106 | 2013 |
| PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2 Y Kato, Y Sai, K Yoshida, C Watanabe, T Hirata, A Tsuji Molecular pharmacology 67 (3), 734-743, 2005 | 100 | 2005 |
